By Andrea Shalal and Emma Farge
(Reuters) – The United States, the European Union, India and South Africa have reached an interim agreement on important elements of a limited intellectual property exemption for Covid-19 vaccines after lengthy negotiations, sources familiar with the matter said. agreement this tuesday.
The interim agreement between the four members of the World Trade Organization (WTO) still needs formal approval from the parties before it can be considered official, according to the sources.
This would only apply to Covid-19 vaccine patents, with much more limited scope than the WTO’s broad intellectual property waiver proposal, which is backed by the United States, they said.
The interim agreement closely reflects the EU’s compulsory licensing approach and does not include Covid treatments or tests, as well as containing limitations that should exclude China from any exemption, one of the sources said.
Spokespeople for the WTO and the US Trade Representative’s office did not immediately respond to requests for comment.
The interim agreement comes after months of negotiations on how to speed up production of coronavirus vaccines in developing countries, where vaccination rates lag far behind rich countries.
(Reporting by Andrea Shalal and David Lawder, in Washington; Emma Farge, in Geneva; and Phil Blenkinsop, in Brussels)
know more
+ Omicron: Unexpected symptom of infection in children worries medical teams
+ Mercadão de SP vendors threaten customers with fruit scam
+ Video: Mother is attacked on social media for wearing tight clothes to take her son to school
+ Horoscope: check today’s forecast for your sign
+ What is known about fluorone?
+ Trick to squeeze lemons becomes a craze on social media
+ ‘Monster Ichthyosaur’ is discovered in Colombia
+ One twin became vegan, the other ate meat. Check the result
+ See which were the most stolen cars in SP in 2021
+ Expedition identifies giant squid responsible for ship sinking in 2011
+ US Agency warns: never wash raw chicken meat
#India #South #Africa #reach #consensus #breaking #patents #Covid #vaccines #ISTOÉ #DINHEIRO